Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death
Context In 2008, the US Food and Drug Administration mandated warning labeling for
anticonvulsant medications regarding the increased risk of suicidal thoughts and behaviors. The …
anticonvulsant medications regarding the increased risk of suicidal thoughts and behaviors. The …
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
E Patorno, AB Goldfine, S Schneeweiss, BM Everett… - Bmj, 2018 - bmj.com
Objective To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter
2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 …
2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 …
Comparative effectiveness and safety of sodium–glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults
OBJECTIVE Both sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like
peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized …
peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized …
Sodium–glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with …
E Patorno, PT Htoo, RJ Glynn… - Annals of internal …, 2021 - acpjournals.org
Background: Both sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-…
peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-…
Conducting real-world evidence studies on the clinical outcomes of diabetes treatments
S Schneeweiss, E Patorno - Endocrine reviews, 2021 - academic.oup.com
Real-world evidence (RWE), the understanding of treatment effectiveness in clinical practice
generated from longitudinal patient-level data from the routine operation of the healthcare …
generated from longitudinal patient-level data from the routine operation of the healthcare …
Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride
E Patorno, S Schneeweiss, C Gopalakrishnan… - Diabetes …, 2019 - Am Diabetes Assoc
OBJECTIVE Using real-world data (RWD) from three US claims data sets, we aim to predict
the findings of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type …
the findings of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type …
Comparative risk of genital infections associated with sodium‐glucose co‐transporter‐2 inhibitors
…, S Schneeweiss, E Patorno - Diabetes, Obesity and …, 2019 - Wiley Online Library
The extent to which sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors increase the risk
of genital infections in routine clinical care, compared with other antidiabetic medications, is …
of genital infections in routine clinical care, compared with other antidiabetic medications, is …
Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
…, S Schneeweiss, E Patorno - New England Journal of …, 2017 - Mass Medical Soc
A study that assessed the risk of diabetic ketoacidosis after the initiation of SGLT2 inhibitor
therapy showed nearly twice the risk as with a DPP4 inhibitor.
therapy showed nearly twice the risk as with a DPP4 inhibitor.
Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study
Background: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose …
Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials
Importance Nonrandomized studies using insurance claims databases can be analyzed to
produce real-world evidence on the effectiveness of medical products. Given the lack of …
produce real-world evidence on the effectiveness of medical products. Given the lack of …